RSV VLP 

Respiratory syncytial virus-like particles (RSV VLPs) are non-infectious, self-assembled nanoparticles that replicate the structure and antigenicity of the RSV virion without carrying viral RNA. These VLPs represent a safe and effective platform for developing vaccines, diagnostics, and therapeutics against RSV, a leading cause of severe respiratory infections in infants, the elderly, and immunocompromised individuals.

Structure of RSV VLPs

RSV VLPs are composed of key structural proteins that form particles resembling the native virus:

  • Fusion Glycoprotein (F): Critical for viral entry into host cells and the primary target for neutralizing antibodies. Both pre-fusion (pre-F) and post-fusion (post-F) conformations are considered in vaccine development, with pre-F showing higher immunogenicity.
  • Attachment Glycoprotein (G): Facilitates viral attachment to host cells; a secondary antigenic target.
  • Matrix Protein (M): Provides structural integrity and drives VLP assembly.
Production Systems

RSV VLPs are typically produced in:

  • Mammalian Cells: Preferred for generating glycosylation and post-translational modifications similar to native RSV proteins, particularly for the F and G glycoproteins.
  • Insect Cells: Employing the baculovirus expression system for high-yield and cost-effective production.
  • Plant-Based Systems: Emerging as a scalable and affordable alternative for producing RSV VLPs.
Applications
  • Vaccines
    • Prophylactic Vaccines: RSV VLP-based vaccines aim to elicit robust neutralizing antibody responses against the F protein, particularly in its pre-fusion conformation, to prevent RSV infection.
    • Maternal Vaccines: Designed to immunize pregnant women, providing passive immunity to newborns.
    • Elderly Vaccines: Targeting at-risk populations with enhanced immunogenic formulations.
  • Diagnostics
    • RSV VLPs are used as antigens in serological assays to detect RSV-specific antibodies, aiding in surveillance and diagnosis.
  • Immunological Research
    • Serve as tools for studying RSV-host interactions, immune response mechanisms, and vaccine efficacy.

RSV virus-like particles are a promising platform for combating RSV infections through safe and effective vaccines. Advances in VLP technology, including the use of pre-fusion F protein and novel adjuvants, aim to address challenges and optimize their application in preventing RSV-related morbidity and mortality worldwide.

For Price Contact info@affigen.com 0.0 USD
For Price Contact info@affigen.com 0.0 USD
For Price Contact info@affigen.com 0.0 USD
For Price Contact info@affigen.com 0.0 USD